A Phase I, Open-label Trial to Investigate Metabolism and Pharmacokinetics of a Single Dose of [14C] BI 1358894 Administered as Oral Solution (Part 1) and Multiple Doses of BI 1358894 Administered as Film-coated Tablets (Part 2) in Healthy Male Volunteers
Latest Information Update: 03 Mar 2025
At a glance
- Drugs BI 1358894 (Primary)
- Indications Borderline personality disorders; Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 12 Jan 2021 Status changed from active, no longer recruiting to completed.
- 21 Dec 2020 Status changed from recruiting to active, no longer recruiting.
- 02 Nov 2020 Status changed from not yet recruiting to recruiting.